Back to results
US 2025/0367176 A1Published application
Methods of treating gastrointestinal stromal tumors
AssigneeDeciphera Pharmaceuticals, LLC
InventorsRodrigo Ruiz Soto, Oliver Rosen, Jama Pitman
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.
Claims11
1-3. (canceled)
A method of treating a Grade 2, Grade 3, or Grade 4 treatment-emergent adverse event in a patient suffering from an advanced gastrointestinal stromal tumor while being administered 100 to 600 mg ripretinib daily comprising:
- withholding administration of ripretinib for 7 days;
- administering to the patient 100 to 600 mg ripretinib once daily if the patient achieves a less than or equal to Grade 1 of the treatment-emergent adverse event, or administering to the patient 100 mg ripretinib once daily for at least 28 days if the patient does not achieve a less than or equal to Grade 1 of the treatment-emergent adverse event;
- wherein the treatment-emergent adverse event is selected from the group consisting of alopecia, fatigue, nausea, constipation, decreased appetite, diarrhea, weight decreased, lipase increased, muscle spasms, abdominal pain, vomiting, anemia, cough, dry skin, dyspnea, headache, back pain, dizziness, rash, hypokalaemia, hypophosphataemia, actinic keratosis, blood bilirubin increase, amylase increased, insomnia, seborrhoeic keratosis, urinary tract infection, dysgeusia, pain in extremity, blood creatine phosphokinase increased, upper respiratory tract infection, rash maculo-papular, hypomagnesaemia, pruritus, skin papilloma, and vision blurred.
Dependencies are inferred from the claim text.